Compare · ACET vs NVO
ACET vs NVO
Side-by-side comparison of Adicet Bio Inc. (ACET) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACET and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 2826.3x ACET ($67.9M).
- Over the past year, ACET is down 40.1% and NVO is down 44.5% - ACET leads by 4.4 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 1 for ACET).
- NVO has more recent analyst coverage (25 ratings vs 11 for ACET).
- Company
- Adicet Bio Inc.
- Novo Nordisk A/S
- Price
- $7.32-10.62%
- $41.86-2.52%
- Market cap
- $67.9M
- $191.82B
- 1M return
- -14.49%
- -8.57%
- 1Y return
- -40.10%
- -44.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 7
- Recent ratings
- 11
- 25
Adicet Bio Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACET
- Amendment: SEC Form 10-K/A filed by Adicet Bio Inc.
- Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
- SEC Form S-8 POS filed by Adicet Bio Inc.
- SEC Form 10-Q filed by Adicet Bio Inc.
- Adicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
- Jefferies resumed coverage on Adicet Bio with a new price target
- Large owner Ra Capital Management, L.P. disposed of 250,000 shares (SEC Form 4)
- SEC Form DEFA14A filed by Adicet Bio Inc.
- SEC Form DEF 14A filed by Adicet Bio Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates